Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global leader in the field of analytical instruments and software solutions. For nearly six decades, the company has pioneered advancements in chromatography, mass spectrometry, and thermal analysis, catering to life, materials, and food sciences. Headquartered in Milford, Massachusetts, Waters Corp. operates directly in 35 countries, supported by approximately 8,000 employees and 15 manufacturing facilities globally.
Waters' main business segments include Waters, TA Instruments, VICAM, ERA, and Nonlinear Dynamics. The company's diverse product portfolio features ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), chromatography columns, mass spectrometry systems, and laboratory informatics solutions. These innovations empower laboratory-dependent organizations to achieve advancements in healthcare, environmental management, food safety, and water quality.
Waters Corporation serves a wide array of customers, including biopharmaceutical companies (57% of sales), industrial clients (31% of sales), and academic/government institutions (12% of sales). The company’s products are available in over 100 countries, ensuring a broad market reach.
Recent achievements include the launch of new accessories for TA Instruments Discovery Hybrid Rheometers, designed for battery formulation analysis, and the introduction of Oasis WAX/GCB and GCB/WAX Cartridges for PFAS analysis. These innovations reflect the company’s commitment to addressing emerging scientific challenges and regulatory requirements. Additionally, Waters continues to enhance its mass spectrometry capabilities with products like the ACQUITY QDa II Mass Detector and the Xevo MRT MS, aimed at accelerating research in pharmaceuticals, food, chemicals, and materials.
Financially, Waters Corporation reported first-quarter 2024 sales of $637 million, with a strategic focus on innovation and operational efficiency. Despite a 7% decrease in sales compared to the previous year, the company remains optimistic about future growth, driven by new product launches and higher growth areas.
Waters Corporation stands as a pivotal player in the analytical instruments industry, consistently driving scientific advancements and operational excellence.
Waters Corporation (NYSE:WAT) will host a live webcast for its Q2 2021 financial results on August 3, 2021, at 8:00 a.m. ET. Investors can access the call through Waters' official website. The replay will be available until August 10, 2021. Waters is a leader in specialty measurement, focusing on chromatography, mass spectrometry, and thermal analysis for life, materials, and food sciences. With over 7,400 employees and operations in 35 countries, Waters has a significant global presence.
Waters Corporation (NYSE:WAT) has launched the TRIOS AutoPilot software, enhancing its thermal analyzer product line under the TA Instruments Division. This software allows laboratory staff to develop standard operating procedures (SOPs) up to 25% faster and eliminates transcription errors, improving productivity and consistency in thermal analysis. It utilizes Google’s Blockly interface, making it user-friendly for script creation without advanced programming skills. The TRIOS AutoPilot includes built-in compliance features, ensuring regulatory adherence, and is available globally.
Waters Corporation (NYSE:WAT) has expanded its collaboration with Singapore's Bioprocessing Technology Institute (BTI) to enhance analytics in glycomics and metabolomics. The partnership aims to improve the rapid identification of complex biomolecules that are crucial for biologics manufacturing. Utilizing advanced instruments like the SYNAPT™ mass spectrometry system, the project addresses the challenges of characterizing biopharmaceuticals through data analytics and machine learning. This collaboration builds on a successful relationship since 2014, targeting cost reduction and efficiency in biomanufacturing processes.
Waters Corporation (NYSE: WAT) has appointed Wei Jiang to its Board of Directors, effective July 14, 2021. Wei currently serves as Executive Vice President at Bayer Pharmaceuticals for the China and APAC regions. His expertise in driving results in fast-growing markets, particularly in China, is viewed as a significant asset for Waters. Dr. Udit Batra, CEO, notes that Wei's experience aligns with the company's growth strategy in the pharmaceutical sector. Wei expressed enthusiasm about contributing to Waters' ongoing transformation, highlighting growth potential in China's pharma market.
Waters Corporation (NYSE:WAT) has launched the Waters Arc Premier System, the first liquid chromatography system designed for 2.5 – 3.5 micron columns featuring MaxPeak High Performance Surface (HPS) technology. This system reduces analyte-surface interactions, thereby improving analytical results for laboratories. Benefits include increased sensitivity, reproducibility, and potential savings of 2-3 days per assay by eliminating passivation. The combination of the Arc Premier System and MaxPeak Premier Columns aims to enhance productivity, accuracy, and confidence in pharmaceutical analysis.
Waters Corporation (NYSE:WAT) has launched the Waters™ SELECT SERIES™ MRT, an advanced mass spectrometer integrating Multi Reflecting Time-of-Flight (MRT) technology with enhanced DESI and new MALDI imaging sources. This device allows for rapid, precise identification of molecules, achieving speeds of up to 10Hz without losing mass accuracy. The SELECT SERIES MRT boasts a resolution of 200,000 FWHM, setting a new standard in mass spectrometry. Shipments are slated to begin in Q4 of this year, promising significant advancements in biological research and imaging applications.
Waters Corporation (NYSE:WAT) has launched a new RUO LC-MS test method, the SARS-CoV-2 LC-MS Kit, to enhance infectious disease research. This innovative method allows for the direct detection and quantification of SARS-CoV-2 Nucleocapsid (NCAP) peptides, yielding highly accurate results. Developed in collaboration with various research entities, this method aims to support high-throughput screening with reduced reliance on PCR reagents. The kit can quantify low levels of NCAP peptides, facilitating impactful studies on infection stages and future pandemic preparedness.
Waters Corporation (NYSE: WAT) reported first quarter 2021 sales of $609 million, up 31% from $465 million in Q1 2020. EPS rose to $2.37 (GAAP) from $0.86 yoy. Net cash from operations reached $218 million, an increase from $152 million. Instrument sales grew 49%, with pharmaceutical sales up 32%. The company anticipates full-year 2021 constant-currency sales growth of 8% to 11% and non-GAAP EPS of $9.85 to $10.05. The Q1 earnings call is scheduled for May 5, 2021.
Waters Corporation (NYSE:WAT) will present at the Bank of America Securities 2021 Virtual Health Care Conference on May 12, 2021, at 2:00 PM EST. CEO Udit Batra will address the investment community, discussing the company’s innovations in chromatography and mass spectrometry that have served the life sciences for over 60 years. Waters, a leader in specialty measurement, has a global workforce of 7,400 and operates in 35 countries.
FAQ
What is the current stock price of Waters (WAT)?
What is the market cap of Waters (WAT)?
What industries does Waters Corporation serve?
What are some of Waters Corporation's recent product launches?
How does Waters Corporation contribute to scientific advancements?
What is the significance of the TA Instruments Discovery Hybrid Rheometers?
How is Waters Corporation performing financially?
Where is Waters Corporation headquartered?
How many employees does Waters Corporation have?
What are TA Instruments' main products?
What is the significance of the Oasis WAX/GCB Cartridges?
How can I access Waters Corporation's financial results?
